Devdiscourse
Development News Edition
Give Feedback
VisionRI - Urban Development

USFDA inspection at Indore facility ends with zero observations: Cipla


PTI new delhi India
Updated: 17-05-2019 22:44 IST
USFDA inspection at Indore facility ends with zero observations: Cipla

Image Credit: Flickr

Drug firm Cipla Friday said the US health regulator conducted a post-approval inspection at its Indore facility, and it ended with zero observations.

"We would like to inform you that the USFDA (US Food and Drug Administration) conducted a post-approval inspection at our Indore facility from 13th May to 17th May, 2019. The inspection ended with zero observations," the company said in a BSE filing.

Shares of Cipla closed at Rs 543.95 apiece on the BSE, down 1.2 per cent from its previous close.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

READ MORE ON :

health regulator

Indore

COUNTRY : India

POST A COMMENT